Overview
Optimizing Ischemic Outcomes in ACS: Formulating Antiplatelet Therapies Across Complex Clinical Scenarios
Highlights from the 2018 Advanced Endovascular and Coronary Intervention Global Summit
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity.
This activity features symposium highlights from the C3 Advanced Endovascular and Coronary Intervention Global Summit, which took place June 2018 in Orlando, Florida. A panel of faculty experts discuss topics in ACS treatment optimization, including:
• Improving individualized dual antiplatelet regimens in complex patients
• Performing genetic testing to guide DAPT
• Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits
• Improving individualized dual antiplatelet regimens in complex patients
• Performing genetic testing to guide DAPT
• Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other clinicians who manage thrombotic risks across diverse patient populations.
The American College of Cardiology (ACC) and the American Hospital Association (AHA) regularly develop and update practice guidelines in order to improve and expand practice within coronary heart disease (CHD). The latest guidelines recommend a tailored approach to antiplatelet therapy, recommending 12 months of dual antiplatelet therapy (DAPT) as a baseline, but also consideration of shorter dual anti-platelet therapy in high bleeding risk patients and longer DAPT in patients without high bleeding risk. The guidelines also outline consideration of newer, 3rd generation antiplatelet agents in patients with acute coronary syndrome. Given these advances in the practical care setting, it is important for clinicians to be familiar with current best practices and ACC/AHA recommendations so that they may be applied and ensure optimal treatment of patients with CHD.
Upon completion of this activity, participants will be able to:
• Discuss the latest guidelines for antiplatelet therapy in ACS
• Compare and contrast the pharmacodynamic properties of antiplatelet therapies
• Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
• Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk
• Discuss the latest guidelines for antiplatelet therapy in ACS
• Compare and contrast the pharmacodynamic properties of antiplatelet therapies
• Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
• Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk
Sponsored by the Academy for Continued Healthcare Learning (ACHL) and Interventional Academy.
Supported by an educational grant from AstraZeneca.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Marc P. Bonaca, MD, MPH
Assistant Professor, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Boston, MA
Bryan Kluck, DO
Cardiologist
Lehigh Valley Health Network
Lehigh Valley Health Network
Allentown, PA
Sandeep Nathan, MD, MSc
Associate Professor of Medicine
Medical Director, Cardiac Intensive Care Unit
Director, Interventional Cardiology Fellowship Program
Co-Director, Cardiac Catheterization Laboratory
Heart and Vascular Center, University of Chicago Medicine
Chicago, IL
Christian T. Ruff, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
ACHL requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. The following financial relationships have been provided:
Marc Bonaca, MD, MPH
Consultant: Aralez, AstraZeneca, Bayer, Janssen, Merck
Research Support: MedImmune, Merck, Amgen, AstraZeneca
Bryan Kluck, DO
Board Member/Advisory Panel: Boston Scientific Corporation, Janssen
Speakers Bureau: Aralez, Boehringer Ingelheim
Sandeep Nathan, MD, MSc
Consultant: AstraZeneca, Cardiovascular Systems, Inc., Janssen, Maquet, Medtronic, Merit Medical, Terumo Medical Corporation
Speakers Bureau: Cardiovascular Systems, Inc., Janssen
Christian Ruff, MD, MPH
Board Member/Advisory Panel: Bayer Healthcare, Boehringer Ingelheim, Daiichi Sankyo, Inc., Janssen, Portola
Consultant: Boehringer Ingelheim, Daiichi Sankyo, Inc.
Research Support: Boehringer Ingelheim, Daiichi Sankyo, Inc., MedImmune, NIH
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 66% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ACHL and Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
ACHL designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACHL designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.